Andrew Leber

Biotherapeutics, Inc.

$4,071,154

Attributed

$4,071,154

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY2019–25

$2M$1.5M$1M$500K$0

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$4,071,154 · 8

By mechanism

R44$2,719,923 · 3

R43$1,351,231 · 5

Top collaborators

No co-investigators on record.

Most similar at Biotherapeutics, Inc.

Same institution · by research overlap

Raquel Hontecillas$3,315,956
Nuria Tubau Juni$2,445,560
Ken Carter$148,288

Others in their field

Other Emerging Leaders on “Oral”

Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
Susan Abushakra · Alzheon, Inc.$50,765,244
John Damon Chodera · Sloan-Kettering Inst Can Research$40,061,627
Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Gary Fanger · Rise Therapeutics, Llc$23,676,385
James Dale Berry · Brigham And Women'S Hospital$15,344,018

Research focus

OralReceptorTreatment EfficacyPublic Health RelevanceDosePharmaceutical PreparationsBiological Response Modifier TherapySmall Business Innovation Research GrantRattusMouse ModelPrecision MedicineSafetyCommercial ApplicationInflammationAutoimmune DiseasesPrecision HealthLeadIn VitroBiotechnologyPathway InteractionsClinical TrialsNovel TherapeuticsInflammatory Bowel DiseasesLigands